The WADA Prohibited List and Peptides (2026)

Most regulatory writing about peptides focuses on one axis: is a compound lawful to buy and sell in a given country? But for athletes subject to drug testing, there is a second, entirely separate axis — the World Anti-Doping Agency (WADA) Prohibited List. The two are decided by different bodies, answer different questions, and can point in opposite directions. This is an informational explainer on how the Prohibited List treats peptide classes in 2026 and why it sits apart from the research-use framing. It is not legal, medical, or anti-doping advice.

What the Prohibited List actually is

The Prohibited List is published annually by WADA and names the substances and methods prohibited in sport. It is part of the broader World Anti-Doping Code, adopted by international federations, national anti-doping organisations, and major event organisers. The List takes effect on a fixed date each year and is the authoritative reference for what a tested athlete may not use.

Crucially, the List is a sport-eligibility framework, not a medicines law. It governs whether a competing athlete may have a substance in their body — not whether the general public may lawfully buy it. That distinction is the entire point of this article.

How the List handles peptides: by class, not by name

The most important structural feature for peptides is that the Prohibited List works largely by class and mechanism, not by enumerating every individual molecule. Several categories are directly relevant:

• Peptide Hormones, Growth Factors, Related Substances and Mimetics — a broad category that captures hormone-like peptides and agents acting through related pathways.
• Growth hormone secretagogues and releasing factors — agents that stimulate the body's own growth-hormone axis fall within the relevant category by mechanism.

Because the framework is class-based, a compound can fall under a prohibited category even if it is not listed by name. Many categories explicitly include language covering "other substances with similar chemical structure or similar biological effect(s)." For an athlete, "it's not on the list by name" is therefore not a safe conclusion — the mechanism is what matters. Our overview of growth-hormone-secretagogue mechanisms explains the pathway that places that whole class within scope.

Why anti-doping status and legality are different axes

This is the conceptual heart of the topic. Whether a compound is lawful in a jurisdiction is a medicines and consumer-protection question, decided by bodies like the FDA, the EMA, or Health Canada. Whether a compound is permitted in sport is an anti-doping question, decided under the WADA Code by sport authorities. The two are independent:

• A substance can be lawful to possess in a country and still be prohibited in sport.
• The research-use framing — covered in our legal-status overview — addresses the medicines axis only. It says nothing about anti-doping status.

A "for laboratory research use only" label is not an anti-doping clearance. The label concerns classification and marketing outside the drug channel; the Prohibited List concerns what may be in a competing athlete's body. Conflating the two is the central error this article exists to prevent.

In-competition vs out-of-competition, and TUEs

Two further nuances are worth noting for completeness, without turning this into advice. Some substances are prohibited at all times, while others are prohibited in-competition only — and the peptide hormone and growth-factor categories generally sit in the always-prohibited group. Separately, an athlete with a genuine medical need may, in defined circumstances, apply for a Therapeutic Use Exemption (TUE) through the proper process. Both of these are governed entirely by anti-doping authorities and the athlete's own organisation. They are mentioned here only to show that the framework has its own internal structure — not as anything a reader should act on.

What this means in practice

The honest, conservative summary for anyone subject to testing:

• Check the source, not a secondary article. The current Prohibited List and your national or international anti-doping organisation are the only authoritative references. Lists change yearly.
• Mechanism beats names. A class-based framework means absence from the List by name is not clearance.
• Legality is not eligibility. Lawful to buy does not mean permitted in sport — they are separate questions with separate answers.
• Research-use framing is irrelevant to anti-doping. It addresses a different axis entirely.

For readers approaching peptides purely from the research side, the catalog covers compound-specific profiles — for example CJC-1295 / Ipamorelin, ipamorelin, and tesamorelin — with the mechanism-focused view under growth-hormone research peptides, the full catalog, and methodology in our research report. None of that catalog content is anti-doping guidance; it is research-framed information.

Bottom line

The WADA Prohibited List is a sport-eligibility framework that sits on a completely different axis from medicines law and from the research-use framing. It addresses several peptide classes — peptide hormones, growth factors, and related substances, and growth-hormone secretagogues — largely by category and mechanism rather than by naming every molecule, which means a compound can be prohibited in sport without appearing by name. For any tested athlete, the only sound move is to consult the current List and their anti-doping organisation directly; a research-use label says nothing about whether a substance is permitted in competition.

For laboratory research use only. Not for human consumption. This article is informational and is not legal, medical, or anti-doping advice; tested athletes should consult the current WADA Prohibited List and their anti-doping organisation.

Related guides:

• The Legal Status of Research Peptides in 2026 — the medicines axis, separate from anti-doping
• Growth Hormone Secretagogue Mechanisms — the pathway that places a whole class within scope
• Peptide Legal Status by Region — how the legality axis varies across markets